Financial Results
Praxis Precision Medicines Inc. reported a second‑quarter loss of $2.87 per share for the quarter ended 30 June 2026, surpassing analyst expectations of a $3.67 loss by $0.80. The net loss for the quarter was $83.7 million, compared with a net loss of $71.1 million in the same quarter of the prior year. Shares of the company rose 6.5 % in pre‑market trading following the release.
FDA Interactions
The company completed mid‑cycle meetings with the U.S. Food and Drug Administration for its two pipeline candidates, ulixacaltamide HCl and relutrigine. The FDA identified no major safety or efficacy concerns and indicated that no advisory committee meetings are planned. Ulixacaltamide HCl received a PDUFA target date of 29 January 2027 for the treatment of essential tremor, while relutrigine received a PDUFA target date of 27 December 2026 for SCN2A and SCN8A developmental and epileptic encephalopathies. FDA Bioresearch Monitoring inspections for both programs were completed without any Form FDA 483 observations.
Expenses
Research and development expenses increased to $69.4 million in the quarter, up from $63.0 million in the comparable prior‑year quarter, primarily reflecting higher costs associated with the Solidus platform and additional personnel. General and administrative expenses rose to $27.5 million from $13.1 million a year earlier, driven by increased professional services and personnel‑related costs.
Breakthrough Therapy Designation
Praxis received its third Breakthrough Therapy Designation for elsunersen after positive results from the EMBRAVE Part A trial targeting seizures associated with SCN2A developmental and epileptic encephalopathy.
Cash Position
As of 30 June 2026, the company held approximately $1.4 billion in cash and investments, up from $926.1 million at 31 December 2025. Management indicated that this cash balance is expected to fund operations into 2028.